ArticleCureus2025
Luseogliflozin Persistently Lowers Glycemia and Body Weight Over a Period of Two Years in Patients With Type 2 Diabetes.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSodium-glucose co-transporter-2 inhibitor (SGLT2i) was introduced as an oral hypoglycemic agent. Thereafter, it was revealed that SGLT2i had multifaced effects, such as renal function and heart failure. Luseogliflozin is one of the SGLT2i. However, the long-term effects of luseogliflozin on glycemic control, body weight, and body mass index have not yet been established.
aimsThis study aimed to determine the long-term effects of luseogliflozin, an SGLT2i, on plasma glucose (PG), body weight (BW), body mass index (BMI), and blood pressure (BP) in patients with type 2 diabetes.
methodsLuseogliflozin was administered continuously in an outpatient clinic for at least two years to 35 SGLT2i-naive patients. Random plasma glucose (RPG), hemoglobin A1c (HbA1c) level, BW, BMI, and BP were measured every six months.
resultsAt baseline, the patients had a median age of 63 years and a median diabetes duration of seven years. The mean RPG levels at the initiation of luseogliflozin and after 1 and 2 years were 213.5, 155.7, and 164.4 mg/dL, respectively. The reductions from baseline at both 1 year (p<0.001) and 2 years (p=0.012) were statistically significant. Compared with the baseline, the mean HbA1c level significantly decreased by 0.98% after 1 year (p<0.001) and by 1.08% after 2 years (p<0.001), respectively. The mean BMI significantly decreased from 27.41 kg/m² at baseline to 26.53 kg/m² after 1 year (p<0.001) and 26.37 kg/m² after 2 years (p<0.001). Systolic/diastolic blood pressure, initially (138.2/79.2 mmHg), was reduced to 132.9/74.5 mmHg after 1 year, with statistically significant declines in both systolic (p=0.035) and diastolic (p=0.016) pressure compared to baseline.
conclusionsThe effects of luseogliflozin on glucose and BW reduction were sustained for at least two years, indicating similarity to other SGLT2 inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.